[
    [
        {
            "time": "",
            "original_text": "复星医药(02196)拟向激励对象授予限制性股票不超过240.72万股",
            "features": {
                "keywords": [
                    "复星医药",
                    "限制性股票",
                    "激励计划"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(02196)拟向激励对象授予限制性股票不超过240.72万股",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药：发布2021年限制性股票激励计划",
            "features": {
                "keywords": [
                    "复星医药",
                    "2021年",
                    "限制性股票",
                    "激励计划"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：发布2021年限制性股票激励计划",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "复星医药(600196.SH)拟授出不超过240.72万股A股限制性股票",
            "features": {
                "keywords": [
                    "复星医药",
                    "A股",
                    "限制性股票",
                    "激励计划"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(600196.SH)拟授出不超过240.72万股A股限制性股票",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药(600196.SH)拟推不超过240.72万股限制性股票激励计划",
            "features": {
                "keywords": [
                    "复星医药",
                    "限制性股票",
                    "激励计划"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(600196.SH)拟推不超过240.72万股限制性股票激励计划",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【异动股】复星医药(02196-HK)跌3.11%",
            "features": {
                "keywords": [
                    "复星医药",
                    "异动股",
                    "下跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】复星医药(02196-HK)跌3.11%",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-03-12",
            "original_text": "智通港股通持股分析|3月12日",
            "features": {
                "keywords": [
                    "智通",
                    "港股通",
                    "持股分析"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通持股分析|3月12日",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "辉瑞疫苗无症状感染保护力达94%；GSK/Vir中和抗体降低住院/死亡风险85%",
            "features": {
                "keywords": [
                    "辉瑞疫苗",
                    "无症状感染",
                    "保护力",
                    "GSK/Vir",
                    "中和抗体",
                    "住院",
                    "死亡风险"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "辉瑞疫苗无症状感染保护力达94%；GSK/Vir中和抗体降低住院/死亡风险85%",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]